1 The National Institute of Neurological Disorders andStroke rt-PA Stroke Study Group. Tissue plasminogenactivator for acute ischemic stroke[J]. N Engl J Med,1995, 333:1581-1588.2 Berkhemer OA, Fransen PS, Beumer D, et al. Arandomized trial of intraarterial treatment for acuteischemic stroke[J]. N Engl J Med, 2015, 372:11-20.3 Saver JL, Goyal M, Bonafe A, et al. SWIFT PRIMEInvestigators. Stent-retriever thrombectomy afterintravenous t-PA vs t-PA alone in stroke[J]. N Engl JMed, 2015, 372:2285-2295.4 Campbell BC, Mitchell PJ, Kleinig TJ, et al.Endovascular therapy for ischemic stroke with perfusion-imaging selection[J]. N Engl J Med, 2015,372:1009-1018.5 Goyal M, Demchuk AM, Menon BK, et al. Randomizedassessment of rapid endovascular treatment of ischemicstroke[J]. N Engl J Med, 2015, 372:1019-1030.6 Jovin TG, Chamorro A, Cobo E, et al. Thrombectomywithin 8 hours after symptom onset in ischemicstroke[J]. N Engl J Med, 2015, 372:2296-2306.7 中国卒中学会, 中国卒中学会神经介入分会, 中华预防医学会卒中预防与控制专业委员会介入学组. 急性缺血性卒中血管内治疗中国指南2015[J]. 中国卒中杂志,2015, 10:590-606.8 Powers WJ, Derdeyn CP, Biller J, et al. 2015 AmericanHeart Association/American Stroke Associationfocused update of the 2013 guidelines for the earlymanagement of patients with acute ischemic strokeregarding endovascular treatment:a guideline forhealthcare professionals from the American HeartAssociation/American Stroke Association[J]. Stroke,2015, 46:3020-3035.9 Huang X, Cheripelli BK, Lloyd SM, et al. Alteplaseversus tenecteplase for thrombolysis after ischaemicstroke (ATTEST):a phase 2, randomised, openlabel,blinded endpoint study[J]. Lancet Neurol, 2015,14:368-376.10 Coutts SB, Dubuc V, Mandzia J, et al. Tenecteplasetissue-type plasminogen activator evaluation forminor ischemic stroke with proven occlusion[J].Stroke, 2015, 46:769-774.11 Albers GA, von Kummer R, Truelsen T, et al. Safetyand eff icacy of desmoteplase given 3-9h af terischaemic stroke in patients with occlusion or highgradestenosis in major cerebral arteries (DIAS-3):adouble-blind, randomised, placebo-controlled phase 3trial[J]. Lancet Neurol, 2015, 14:575-584.12 Saver JL, Starkman S, Eckstein M, et al. Prehospitaluse of magnesium sulfate as neuroprotection in acutestroke[J]. N Engl J Med, 2015, 372:528-536.13 Llovera G, Hofmann K, Roth S, et al. Results ofa preclinical randomized controlled multicentertrial (pRCT):Anti-CD49d treatment for acute brainischemia[J]. Sci Transl Med, 2015, 7:1-10.14 Ying Xian Y, Wu J, O’Brien EC, et al. Real worldeffectiveness of warfarin among ischemic strokepatients with atrial fibrillation:observational analysisfrom Patient-Centered Research into OutcomesStroke Patients Prefer and Effectiveness Research(PROSPER) study[J]. BMJ, 2015, 351:h3786.15 O’Brien EC, Greiner MA, Xian Y, et al. Clinicaleffectiveness of statin therapy af ter ischemicstroke:primary results from the statin therapeuticarea of the Patient-Centered Research Into OutcomesStroke Patients Prefer and Effectiveness Research(PROSPER) Study[J]. Circulation, 2015, 132:1404-1413.16 Huo Y, Li J, Qin X, et al. Efficacy of folic acid therapyin primary prevention of stroke among adults withhypertension in China:the CSPPT randomized clinicaltrial[J]. JAMA, 2015, 313:1325-1335.17 Zaidat OO, Fitzsimmons BF, Woodward BK, et al.Effect of a balloon-expandable intracranial stentvs medical therapy on risk of stroke in patientswith symptomatic intracranial stenosis:the VISSITrandomized clinical trial[J]. JAMA, 2015, 313:1240-1248.18 Compter A, van der Worp HB, Schonewille WJ, et al.for the VAST investigators. Stenting versus medicaltreatment in patients with symptomatic vertebralartery stenosis:a randomised open-label phase 2trial[J]. Lancet Neurol, 2015, 14:606-614.19 Amin-Hanjani S, Du X, Rose -Finnel l L, e tal. Hemody nami c feat ures of symptomat icvertebrobasilar disease[J]. Stroke, 2015, 46:1850-1856.20 CADISS trial investigators. Antiplatelet treatmentcompared with anticoagulation treatment for cervicalartery dissection (CADISS): a randomised trial[J].Lancet Neurol, 2015, 14:361-367.21 Sposato LA, Cipr iano LE, Saposnik G, et al.Diagnosis of atrial fibrillation after stroke andtransient ischaemic attack:a systematic review andmeta-analysis[J]. Lancet Neurol, 2015, 14:377-387.22 Abdul-Rahim AH, Perez AC, Fulton RL, et al. Risk ofstroke in chronic heart failure patients without atrialfibrillation:Analysis of the Controlled Rosuvastatinin Multinational Trial Heart Failure (CORONA) andthe Gruppo Italiano per lo Studio della Sopravvivenzanell'Insufficienza Cardiaca-Heart Failure (GISSI-HF)Trials[J]. Circulation, 2015, 131:1486-1494.23 AVERT Trial Collaboration group. Efficacy and safetyof very early mobilisation within 24h of stroke onset(AVERT):a randomised controlled trial[J]. Lancet,2015, 386:46-55.24 Barzel A, Ketels G, Stark A, et al. Home-basedconstraint-induced movement therapy for patients withupper limb dysfunction after stroke (HOMECIMT):acluster-randomised, controlled trial[J]. Lancet Neurol,2015, 14:893-902. |